Likewise, CD13+ CSCs could also be suppressed by a fusion protein, termed NGR-LDP-AE, composed of a CD13-targeted peptide NGR and anti-tumor antibiotic lidamycin, which displayed a prominent anti-tumor effect by killing CD13+ CSCs and suppressing angiogenesis [133]. The gene discussed is CPQ; the disease is neoplasm.